Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,414 matching trials from the live ClinicalTrials.gov search.
Conditions
End Stage Kidney Disease
Interventions
CSL300, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
166
States / cities
Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more
Conditions
Cardiovascular Disease
Interventions
CardioLife
Dietary Supplement
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Completed Not applicable Interventional Results available

Impact of a Corrie Cardiac Rehabilitation Program

NCT05238103
Conditions
Coronary Artery Disease, Myocardial Infarction, Myocardial Ischemia, Coronary Artery Occlusion, Coronary Artery Stenosis Stent, Bypass Graft Occlusion, Valve Heart Disease
Interventions
Corrie Hybrid Cardiac Rehabilitation Program
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
Interventions
Pentoxifylline, Placebo, Standard Treatment
Drug · Other · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Not listed Phase 2Phase 3 Interventional

BioFreedom US IDE Feasibility Trial

NCT02131142
Conditions
Ischemic Heart Disease, Stable Angina, Unstable Angina, Silent Ischemia
Interventions
BioFreedom drug coated coronary stent
Device
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 10 more
Conditions
Coronary Artery Disease
Interventions
ITPR
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Renal Failure, Coronary Artery Disease, Surgery, Surgery-Complications
Interventions
CoQ10 1200 mg orally with Glutathione 1000 mg orally, Group B: Placebo CoQ10 orally and Placebo Glutathione orally
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed No phase listed Observational

The SCRIPPS DES REAL WORLD Registry

NCT00714623
Conditions
Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions
Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Device
Lead sponsor
Paul S Teirstein, MD
Other
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
La Jolla, California
Conditions
Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Ranolazine, Ranolazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more
Conditions
Coronary Artery Disease, Cardiac Disease, Malignancy, Second
Interventions
Not listed
Lead sponsor
LMU Klinikum
Other
Eligibility
18 Years and older
Enrollment
4,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
HeartFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Redwood City, California • Stanford, California • Durham, North Carolina
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Decision-making tool for coronary artery disease treatment
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Coronary Artery Disease
Interventions
PB127 for Injectable Suspension
Drug
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Tucson, Arizona • Burlingame, California • Long Beach, California + 33 more
Conditions
Spinal Cord Injuries, Heart Diseases
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Completed Phase 4 Interventional Results available

Vorapaxar on Thrombin Generation and Coagulability

NCT03207451
Conditions
Coronary Artery Disease, Peripheral Vascular Disease, Myocardial Infarction
Interventions
Vorapaxar, Vorapaxar and Aspirin, Vorapaxar and Clopidogrel, Vorapaxar, Aspirin, and Clopidogrel
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Falls Church, Virginia
Conditions
Coronary Artery Disease, Behavioral
Interventions
Not listed
Lead sponsor
Richard Lane
Other
Eligibility
21 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease
Interventions
Biomarker Assessment
Other
Lead sponsor
CirQuest Labs, LLC
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Jacksonville, Florida • Germantown, Tennessee • Memphis, Tennessee
Conditions
Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
Conditions
Coronary Artery Ischemia
Interventions
blood pressure cuff
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Completed Phase 1 Interventional Results available

Remote-delivered MBCT for SCAD Survivors

NCT04983680
Conditions
Acute Coronary Syndrome, Coronary Artery Disease, Anxiety, Sleep
Interventions
MBCT
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hypercholesterolemia
Interventions
PRO-040201, Placebo
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Active, not recruiting Not applicable Interventional

SELUTION 4 De Novo Small Vessel IDE Trial

NCT05946629
Conditions
Coronary Artery Disease
Interventions
PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
65
States / cities
Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more